The influence of percentage of preradiation needle biopsies with adenocarcinoma and total radiation dose on the pathologic response of unfavorable prostate adenocarcinoma

American Journal of Clinical Pathology

Volumn 117, Issue 6, 2002, Pages 927-934

  Goldstein, Neal S ^a   Kestin, Larry L ^a   Vicini, Frank A ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Brachytherapy; Gleason; Prostate; Prostate specific antigen; PSA; Radiation; Volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL PROTOCOL; DISEASE MARKER; DOSE CALCULATION; DOSE RESPONSE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION RESPONSE; SCORING SYSTEM; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT FAILURE;

EID: 0036265174     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/G4TN-YDK1-8DA2-TFM9     Document Type: Article

References (37)

1. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
2. Prostate brachytherapy: Treatment strategies
3. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: A preliminary report of 434 patients
4. Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up
5. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
6. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer
7. What is the alpha/beta ratio for prostate cancer? rationale for hypofractionated high-dose-rate brachytherapy
8. Radiation inactivation of human prostate cancer cells: The role of apoptosis
9. Fractionation and protraction for radiotherapy of prostate carcinoma
10. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line
11. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma
12. The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost: Correlation with biochemical failure
13. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy
14. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
15. A dose-response study for 1-125 prostate implants
16. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
17. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand?
18. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
19. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy
20. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
21. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
22. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy
23. 3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy
24. Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy
25. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy
26. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer
27. A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: An explanation for a medical anomaly
28. Correlation of serum prostate specific antigen and quantitative immunohistochemistry
29. Histologic differentiation, cancer volume, and pelvic lymph node metastases in adenocarcinoma of the prostate
30. An analysis of microvessel density, androgen receptor, p53 and HER- 2/neu expression and Gleason score in prostate cancer: Preliminary results and therapeutic implications
31. Microvessel density in prostate cancer: Prognostic and therapeutic utility
32. Predictors of pathologic stage in prostate carcinoma: The role of neovascularity
33. Hypoxic regions exist in human prostate carcinoma
34. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues
35. A single positive prostate biopsy in six does not predict a low-volume prostate tumor
36. Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease
37. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis